Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab in Osteoarthritis of the Hip or Knee
NCT02301234Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of fulranumab in osteoarthritis (OA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with Adverse Events at 52 weeks. Started Mar 2015; status: completed.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02301234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301234.